Список литературы

1. Morton LM, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992 - 2001. Blood. 2006; 107 (1): 265 - 76

2. Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. European journal of haematology. 2008; 81 (4): 253 - 8

3. Jemal A, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57 (1): 43 - 66

4. Dores GM, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007; 139 (5): 809 - 19

5. Hallek M, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111 (12): 5446 - 56

6. Rawstron AC. Monoclonal B-cell lymphocytosis. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2009: 430 - 9.

7. Ghia P, et al. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood. 2004; 103 (6): 2337 - 42

8. Rawstron AC, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359 (6): 575 - 83

9. Dagklis A, et al. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Blood. 2009; 114 (1): 26 - 32

10. Nieto WG, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood. 2009; 114 (1): 33 - 7

11. Shanafelt TD, et al. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010; 24 (3): 512 - 20

12. Scarfo L, et al. CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? Semin Cancer Biol. 2010; 20 (6): 384 - 90

13. Rawstron AC, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3,5% of adults with normal blood counts. Blood. 2002; 100 (2): 635 - 9

14. Rawstron AC, et al. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry. Part B, Clinical cytometry, 2010. 78 Suppl 1: S19 - 23

15. Dagklis A, et al. Monoclonal B lymphocytosis in the general population. Leuk Lymphoma. 2009; 50 (3): 490 - 2

16. Shanafelt TD, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol. 2009; 27 (24): 3959 - 63

17. Scarfo L, et al. Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines? Leukemia. 2012; 26 (7): 1703 - 7

18. Richter MN. Generalized Reticular Cell Sarcoma of Lymph Nodes Associated with Lymphatic Leukemia. Am J Pathol. 1928; 4 (4): 285 - 292

19. Lortholary P, et al. Chronic Lymphoid Leukemia Secondarily Associated with a Malignant Reticulopathy: Richter"s Syndrome. Nouv Rev Fr Hematol. 1964; 4: 621 - 44

20. Mauro FR, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. 1999; 94 (2): 448 - 54

21. Tsimberidou AM, et al. Clinical outcomes and prognostic factors in patients with Richter"s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006; 24 (15): 2343 - 51

22. Tsimberidou AM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006; 107 (6): 1294 - 302

23. Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol. 2012; 156 (1): 50 - 66

24. Rossi D, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011; 117 (12): 3391 - 401

25. Choi WWL, et al. A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. American Association for Cancer Research. 2009; 15 (17): 5494 - 5502

26. Mao Z, et al. IgVH mutational status and clonality analysis of Richter"s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007; 31 (10): 1605 - 14

27. Chigrinova E, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013; 122 (15): 2673 - 82

28. Rossi D, et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009; 50 (4): 604 - 11

29. Lai CL, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003; 36 (6): 687 - 96

30. Westland CE, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology. 2003; 38 (1): 96 - 103

31. Tenney DJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007; 51 (3): 902 - 11

32. International, C.L.L.I.P.I.w.g., An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a metaanalysis of individual patient data. Lancet Oncol. 2016; 17 (6): 779 - 90

33. Hallek M, et al., Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376 (9747): 1164 - 74

34. Fischer K, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016; 127 (2): 208 - 15

35. Tam, CS, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014; 124 (20): 3059 - 64

36. Strati P, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014; 123 (24): 3727 - 32

37. Fischer K, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011; 29 (26): 3559 - 66

38. Fischer K, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012; 30 (26): 3209 - 16

39. Eichhorst B, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016; 17 (7): 928 - 42

40. Geisler CH, et al. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood. 2014; 123 (21): 3255 - 62

41. Lepretre S, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012; 119 (22): 5104 - 10

42. Catovsky D, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007; 370 (9583): 230 - 9

43. Eichhorst BF, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107 (3): 885 - 91

44. Flinn IW, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007; 25 (7): 793 - 8

45. Eichhorst BF, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009; 114 (16): 3382 - 91

46. Han T, et al. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer. 1973; 31 (3): 502 - 8

47. Knospe WH, Loeb V. Biweekly chlorambucil treatment of lymphocytic lymphoma. Cancer Clin Trials. 1980; 3 (4): 329 - 36

48. Foa R, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014; 89 (5): 480 - 6

49. Hillmen P, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol. 2014; 32 (12): 1236 - 41

50. Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370 (12): 1101 - 10

51. Hillmen P, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015; 385 (9980): 1873 - 83

52. Foon KA, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009; 27 (4): 498 - 503

53. Foon KA, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012; 119 (13): 3184 - 5

54. Dartigeas C, et al. Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 1 - 7

55. Mato AR, et al., Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol. 2015; 90 (6): 487 - 92

56. Mulligan SP, et al. A randomised dose de-escalation safety study of oral fludarabine, +/- oral cyclophosphamide and intravenous rituximab (OFOCIR) as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged >= 65 years - end of recruitment analysis of response and toxicity of the Australisian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood. 2012; 120 (21): 436 - 436

57. Smolej L, et al. Low-Dose Fludarabine and Cyclophosphamide Combined With Rituximab Is a Safe and Effective Treatment Option for Elderly and Comorbid Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Preliminary Results of Project Q-lite, by the Czech CLL Study Group. Clinical Lymphoma Myeloma and Leukemia. 2011; 11: S261

58. Nikitin E, et al. Randomised Comparison Of FCR-Lite And ClbR (Chlorambucil Plus Rituximab) Regimens In Elderly Patients With Chronic Lymphocytic Leukemia. Hematologica. 2013; 98 (s1): Abstract NS 1147

59. Leblond V, Laribi K, Ilhan O, et al. Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase IIIb Study (MaBLe). Blood. 2012; 120: Abstract 2744

60. Burger JA, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 373 (25): 2425 - 37

61. van Oers MH, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015; 16 (13): 1370 - 9

62. Greil R, et al., Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016; 3 (7): e317 - 29

63. Zagoskina P, Zotina N. Supporting rituximab therapy in chronic lymphocytic leukemia. Program and abstracts of the 2010 EHA Congress, June 10 - 13, 2010; Barcelona, Spain, 2010. Abstract 0778.

64. Byrd, JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371 (3): 213 - 23

65. Byrd JC, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369 (1): 32 - 42

66. Chanan-Khan A, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016; 17 (2): 200 - 11

67. Stilgenbauer S, Hallek M. Chronic lymphocytic leukemia. Treatment and genetic risk profile. Internist (Berl). 2013; 54 (2): 164, 166 - 70

68. Burger JA, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a singlearm, phase 2 study. Lancet Oncol. 2014; 15 (10): 1090 - 9

69. Dreger P, et al., Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014; 124 (26): 3841 - 9

70. Dreger P, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007; 21 (1): 12 - 7

71. Wierda WG, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011; 118 (19): 5126 - 9

72. Mauro FR, et al. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia. 2015; 29 (6): 1360 - 5

73. Conte MJ, et al. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2014; 55 (9): 2079 - 84

74. Omoti CE, Omoti AE. Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol. 2008; 142 (5): 709 - 16

75. Falchi L, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014; 123 (18): 2783 - 90

76. Michallet AS, et al. An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter"s Syndrome. Leuk Lymphoma. 2016; 57 (6): 1474 - 7

77. Vitale C, Ferrajoli A. Richter Syndrome in Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep. 2016; 11 (1): 43 - 51